We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Tango Therapeutics is set to go public with the signing of a definitive merger agreement with the Boxer Capital-sponsored special purpose acquisition company BCTG Acquisition worth up to a total of approximately $353m.
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.